Valneva SE (VLA.VI)
| Previous Close | 6.52 |
| Open | 6.56 |
| Bid | 5.65 x 50000 |
| Ask | 7.07 x 81200 |
| Day's Range | 6.35 - 6.56 |
| 52 Week Range | 2.06 - 6.56 |
| Volume | |
| Avg. Volume | 14,123 |
| Market Cap | 572.949M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
- GlobeNewswire
Valneva Hosts Investor Day in New York City
Live event and webcast TODAY at 10 AM – 12 PM ET Saint-Herblain (France), December 06, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions. Valneva’s Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company’s senior leadership team will highlight Valneva’s
- GlobeNewswire
VALNEVA - Declaration of shares and voting rights: November 30, 2022
VALNEVA Declaration of shares and voting rightsNovember 30, 2022 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: December 5, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this chan
